Fulcrum Therapeutics (FULC, Financial) has seen a significant upgrade in its stock rating by leading analyst firm Leerink Partners. The analyst responsible for this upgrade, Joseph Schwartz, has elevated FULC's rating from "Market Perform" to "Outperform".
Along with the improved rating, Fulcrum Therapeutics (FULC, Financial) also witnessed a notable adjustment in its price target. The new price target set by Joseph Schwartz stands at USD 12.00, which marks an impressive 200% increase from the previous target of USD 4.00.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.